JPRN-jRCTs051220059招募中2 期
A Phase II Study of Ramucirumab and Erlotinib in Treatment-naive Non-Small Cell Lung Cancer Patients with Brain Metastases - SPIRAL-BRAI
Takayama Koichi0 个研究点目标入组 32 人开始时间: 2022年6月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients revealed by head MRI (contrast-enhanced MRI as far as possible) within 28 days before registration (28-day earlier on the same day of the week is acceptable) to have treatment-naive brain metastasis (major axis double the slice thickness or more and 5 mm or more). Symptom-free patients and patients with mild symptoms (remaining controlled for one week or more by anti-brain edema therapy with steroid at dose levels not exceeding 40 mg when converted into prednisolone dose level) are eligible. Patients having undergone stereotactic radiotherapy are eligible if their clinical symptoms are stable and they have recovered from all treatment-related adverse events by the time of registration. Patients planned to receive radiotherapy for brain metastasis must have at least one lesion not covered by irradiation.
- •2)Patients rated histologically or cytologically to have non-small cell lung carcinoma.
- •3)Carcinoma at stage IV or postoperative recurrence not amenable to radical treatment.
- •4)Having received no chemotherapy for the cancer covered by this study. Patients having received preoperative or postoperative chemotherapy are eligible if the final chemotherapy dose is given 6 months or more before the date of registration with this study. Provided patients having received EGFR-TKI during preoperative or postoperative chemotherapy are not eligible.
- •5)EGFR mutation positive (excluding patients confirmed to have T790M mutation).
- •6)Patients able to take oral-dose drugs.
- •7)Age of 20 years old or older at the time of consent obtainment.
- •8)ECOG performance status(PS)of 0-2.
- •9)Patients free of severe disorder of major organs (bone marrow, heart, lungs, liver) and satisfying the criteria given below (the latest data collected within 14 days before registration are used for judgment of eligibility. The 14-day period is counted from the date of registration and includes the same day of the preceding week).
- •Neutrophils >=1,500 /mm3
- •Hemoglobin >=9.0 g/dL
- •Platelets >=100,000 /mm3
- •AST,ALT <=3.0xULN (upper limit of normal range)
- •(Patients with liver metastasis: <=5.0xULN)
- •Total bilirubin <=1.5xULN
- •Serum creatinine <=1.5xULN
- •or creatinine clearance >=40 mL/min
- •SpO2 (Room air) 90% or more
- •PT-INR<=1.5, and APTT longer by 5 seconds or less than the upper limit of normal range (unless receiving anticoagulant therapy)
- •*In patients receiving anticoagulant therapy, such as warfarin, the anticoagulant therapy should be replaced with low-molecular-weight heparin before starting the protocol treatment and then PT-INR<=3.0 should be confirmed.
- •Urinary protein<=1+(test paper method, or less than 1,000 mg/day in 24-hour pooled urine
- •10)No restriction about presence/absence of lesions other than brain lesions (no restriction about presence/absence of measurable lesions according to RECIST1.1). However, thoracic/abdominal CT performed within 28 days before registration is essential (28-day earlier on the same day of the week is acceptable).
- •11)Patients expected to survive for at least 3 months.
- •12)The absence of any of the prior treatments or procedures described below, or if any prior treatments or procedures had been done, the specified period of time has elapsed since the completion of the prior treatments or procedures before registration:
- •i)Stereotactic radiation/Gamma knife therapy for brain metastasis
- •Passage of 1 or more days from the final irradiation day.
- •ii)Surgery for brain metastasis
- •Passage of 7 or more days after surgery.
- •(The presence of untreated
排除标准
- •1)The patient has known to have T790M EGFR mutation
- •2)Having developed grade 3 or higher gastrointestinal bleeding within 3 months before registration or hemoptysis (defined as bright red blood or >= 1/2 teaspoon,regardless of grade) within 2 months before registration.
- •3)Patients with imaging findings suggestive of macrovascular tumor invasion, tumor encasement, or hollowing within the tumor.
- •4) Patients with tumor exposure in the central airway up to the segmental branch.
- •5)Patients having developed severe uncontrollable coagulation disorder or severe hemorrhagic complication within 6 months before registration.
- •6)Patients who have developed deep vein thrombus, pulmonary embolism within 3 months before registration.
- •7)Patients having undergone surgery within 4 weeks before registration.
- •Provided, skin tumor resection and endoscopic surgery are acceptable if one week or more has elapsed after surgery.
- •8) Active double cancer. Synchronous double cancer and metachronous double cancer with disease-free survival of within 2 years requiring treatment will be regarded as double cancer.
- •9)Patients confirmed by MRI or cerebrospinal fluid test to have meningeal dissemination
- •10)Patients having developed cerebrovascular or neurovascular disease (including myocardial infarction, cerebral infarction and transient ischemic attack) or other arterial thromboembolic events within 6 months before registration.
- •11) Patients judged to have developed gastrointestinal perforation within 6 months before registration or to have a risk for perforation (gastrointestinal invasion, metastasis).
- •12)Patients having poorly controlled hypertension (systolic blood pressure remaining 160 mmHg or higher and diastolic blood pressure remaining 100 mmHg or higher for 4 weeks or more).
- •13)Patients having unhealed wound or peptic ulcer.
- •14)Patients having developed fracture within 1 month before registration.
- •15) Patients with poorly controlled metabolic disease (diabetes mellitus) or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain. Provided, patients on continued insulin use are eligible if the condition is rated as been well controlled.
- •16)Local infection or systemic active infection requiring surgical treatment, such as drainage.
- •17)Periodical users of non-steroidal anti-inflammatory drugs (NSAIDs:indomethacin, ibuprofen, naproxen or analogous drugs) or anti-platelet drugs (aspirin, dipyridamole, ticlopidine, clopidogrel or analogous drugs). Provided, low-dose aspirin (325 mg/day or less) is acceptable. NSAIDs are acceptable if 7 days or more have elapsed after switching to acetaminophen.
- •18)Patients rated as Child-Pugh B or severer liver cirrhosis or having hepatic encephalopathy or symptomatic hepatic ascites.
- •19)Active hepatitis B or hepatitis C (Patients testing positive for HBs antibody, HBc antibody or HBs antigen are eligible if the virus level is lower than the detection limit and hepatitis is inactive. Patients testing positive for HCV antibody are eligible if hepatitis is inactive).
- •20)Interstitial pulmonary disease evident on CT scan at the time of registration (positive history or organization of radiation pneumonitis is acceptable).
- •21)Patients judged to be difficult for registration with this study because of clinically significant psychiatric disease.
- •22)Complication by clinically significant ophthalmic disease [example: severe dry eye syndrome (includ
研究者
相似试验
进行中（未招募）
1 期
A study to assess the safety and efficacy of the drugs rituximab and varlilumab in patients with B-cell cancer that did not respond to treatment or has returned.Relapsed or refractory B-Cell malignanciesMedDRA version: 20.0 Level: PT Classification code 10003903 Term: B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10003902 Term: B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000302-37-GBniversity Hospital Southampton Foundation Trust40
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63
尚未招募
2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001non-squamous non-small cell lung cancerJPRN-UMIN000011791Itabashi Chuo Medical Center16
招募中
2 期
Phase II study evaluating Erlotinib/Bevacizumab therapy as a second line therapy for advanced relapsed EGFR mutation positive non-squamous NSCLC patients who received first line combination therapy including platinum and Bevacizumabnon-squamous non-small-cell lung cancerJPRN-UMIN000009603Respiratory Center, Showa University Northern Yokohama Hospital13
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40